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Abstract
Background: Adiponectin, a peptide hormone secreted from the adipose tissue, has anti-diabetic, anti-atherogenic, and anti-inflammato-
ry properties and is also involved in the regulation of angiogenesis. However, there are discrepancies among the results of the published
data regarding its pro- or anti-angiogenic properties. The aim of our study was to examine the direct effect of various adiponectin concen-
trations applied separately or in combination with thalidomide on the growth of the murine endothelial cell line HECa10 in 24- and
72-hour cell cultures.
Material and methods: We used immortalized murine endothelial cell line received from endothelial cells of the mouse peripheral lymph
node. The effect of adiponectin was examined at concentrations from 10–5 to 10–12M. Thalidomide was used at 10–3 M concentration. The
growth of HECa10 cells was assessed by the colorimetric Mosmann method.
Results: We found that adiponectin inhibited the growth of HECa 10 line at all examined concentrations in the 24-hour culture, with
moderate potency. There were no dose- or time-response effects. In the 72-hour cell culture, adiponectin inhibited the growth with the
same or weaker potency and we did not observe its inhibitory effect at 10–12M concentration. There was no beneficial interaction between
adiponectin and thalidomide. In this study, however, thalidomide alone did not cause any inhibitory effect on this cell line.
Conclusions: The obtained data show that adiponectin inhibits endothelial cell growth and may participate in angiogenesis regulation as
an endogenous antiangiogenic factor. (Pol J Endocrinol 2009; 60 (3): 166–171)
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Streszczenie
Wstęp: Adiponektyna jest hormonem peptydowym produkowanym przez tkankę tłuszczową wykazującym działanie przeciwcukrzyco-
we, przeciwmiażdżycowe i przeciwzapalne. Sugerowany jest również jej udział w regulacji procesów angiogenezy. Część autorów uwa-
ża, że adiponektyna stymuluje powstawanie nowych naczyń krwionośnych, podczas gdy inni postrzegają ją jako negatywny regulator
angiogenezy. Celem niniejszej pracy była ocena bezpośredniego wpływu różnych stężeń adiponektyny zastosowanej osobno lub łącznie
z talidomidem na wzrost mysiej linii komórek śródbłonka HECa 10 w hodowli komórkowej 24- i 72-godzinnej.
Materiał i metody: Hodowle prowadzono na mysiej linii komórek śródbłonka HECa 10 otrzymanej w wyniku unieśmiertelnienia pier-
wotnej hodowli komórek HEC pochodzących z pozakapilarnych naczyń żylnych obwodowych węzłów chłonnych myszy. Wpływ adipo-
nektyny badano w stężeniach od 10–5 do 10–12M. Talidomid zastosowano w stężeniu 10–3M. Wzrost komórek śródbłonka oceniano za
pomocą metody kolorymetrycznej Mosmanna.
Wyniki: Adiponektyna hamowała wzrost linii HECa 10 we wszystkich badanych stężeniach w hodowli 24-godzinnej. Jej hamujące dzia-
łanie było umiarkowane. Nie obserwowano zależności dawka-efekt i czas-efekt. W hodowli 72-godzinnej jej hamujące działanie było
podobnie nasilone lub słabsze i nie obserwowano jej hamującego działania w stężeniu 10–12M. Nie wykazano korzystnego współdziałania
adiponektyny z talidomidem, który sam również nie hamował wzrostu badanej linii w porównaniu z grupą kontrolną.
Wnioski: Wykazany hamujący wpływ adiponektyny na wzrost komórek śródbłonka sugeruje udział tego hormonu w regulacji procesów
angiogenezy, jako endogennego czynnika antyangiogennego. (Endokrynol Pol 2009; 60 (3): 166–171)
Słowa kluczowe: adiponektyna, wzrost śródbłonka, in vitro
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Introduction
Adiponectin, also termed apM1 or GBP28 (and its mu-
rine counterpart — Acrp30 or AdipoQ), was originally
identified independently by 4 groups of researchers in
the years 1995 and 1996 as a protein synthesized exclu-
sively by the adipose tissue [1–4]. In 2005, it was shown
that adiponectin is also synthesized and secreted by iso-
lated murine and human cardiomyocytes [5]. Adipo-
nectin has a characteristic NH2-terminal collagen-like
fibrous domain (structurally homologous with collagen
VIII and X) and a COOH-terminal complement C1q-
like globular domain [1–4]. Via its collagen domain,
adiponectin combines to create 3 major oligomeric
forms: a low–molecular weight (LMW) trimer, a mid-
dle–molecular weight (MMW) hexamer, and a high–
molecular weight (HMW) 12- to 18-mer adiponectin [6,
7]. Adiponectin can exist in human plasma as full-length
(fAd) or a smaller, globular fragment (gAd) [8, 9]. Two
receptor forms for adiponectin were described: Adi-
poR1, which is ubiquitously expressed, including the
abundant expression in skeletal muscles with a high
affinity for gAd and low affinity for fAd, and AdipoR2,
which is predominantly expressed in the liver with
a high affinity for fAd form [9].
Adiponectin circulates at relatively high (µg/ml) con-
centrations in the plasma, and although adiponectin is
secreted from the adipose tissue, paradoxically its pla-
sma level is decreased in obesity [2, 10]. Adiponectin
levels correlate negatively with percentage of body fat,
fasting plasma glucose, oral glucose tolerance, apolipo-
proteins (apos) B and E, total and LDL-cholesterol, and
uric acid, and positively correlate with HDL-cholesterol
and apo A-1 [11, 12]. Its levels are significantly lower in
patients with cardiovascular disease [13] and hyperten-
sion [14] and in metabolic syndrome [15]. Adiponectin
concentration also seems to be gender–dependent (less
in men compared than in women), and this is said to be
androgen induced [10, 16, 17].
Adiponectin exhibits insulin-sensitizing effects in
tissues involved in glucose and lipid metabolism and
leads to a reduction of glucose levels in vivo [18]. In
addition to this effect, adiponectin has potent anti-
atherogenic and anti-inflammatory properties such as:
suppression of TNFa-induced inflammatory changes
in endothelial cells, as well as proliferation of myelo-
monocytic progenitors. It also has an inhibitory effect
on phagocytic activity and TNFa secretion from ma-
crophages [19, 20–22]. Moreover, Baranowska et al. [23]
suggest that adiponectin may play a role in the me-
chanisms contributing to prolonged survival, because
in their study plasma adiponectin values in a centena-
rian women group were higher than in any of the other
groups.
Dysregulation of angiogenesis is related to athero-
sclerosis, diabetes, and hypertension. Vascular endothe-
lial cells play a pivotal role in this process. Recent stu-
dies show that adiponectin is also involved in regula-
tion of angiogenesis (both receptor forms for adiponec-
tin, AdipoR1, and AdipoR2 are expressed in endothelial
cells [24]), but the data about its influence on endothe-
lial cell apoptosis and angiogenesis are conflicting. Some
authors suggest that adiponectin stimulates endothe-
lial cell growth and angiogenesis [25, 26], whereas others
perceive it as a negative regulator of angiogenesis,
which potently inhibits endothelial cell proliferation and
migration [27]. Ouchi et al. [25] showed that adiponec-
tin stimulates the differentiation of human umbilical
vein endothelium cells (HUVECs) into capillary-like
structures and exhibits chemoattractant properties
in migration assays. They also tested the effect of adi-
ponectin on blood vessel growth using a mouse Matri-
gel plug and rabbit corneal assays. Their observations
indicate that adiponectin promotes angiogenesis via
activation of the 5'-AMP-activated protein kinase
(AMPK) and phosphatidylinositol 3-kinase (PI3-kina-
se)-Akt-dependent pathways in endothelial cells. Other
studies also provide evidence that due to its ability to
stimulate AMPK-dependent signalling, adiponectin
plays an important role in the process of ischaemia-in-
duced angiogenesis and stimulates angiogenesis in re-
sponse to ischaemic stress [28]. Adiponectin has also
been thought to be essential for the appropriate deve-
lopment of the retinal vasculature because it stimulates
angiogenesis and vascular remodelling in the develo-
ping murine retina [29]. The results of the studies of
Kobayashi et al. [26] are also consistent with a proan-
giogenic function for adiponectin. They revealed that
the HMW fraction of adiponectin suppresses cell death
in serum-deprived HUVEC cultures in a dose-depen-
dent manner. Their data have shown that the AMPK
signalling is essential for these anti-apoptotic activities
of adiponectin on endothelial cells. In contrast to these
data, the study by Bråkenhielm et al. [27] provided evi-
dence that in vitro adiponectin is a direct angiogenesis
inhibitor [it inhibits bovine capillary endothelial (BCE)
cell growth] and induces apoptosis in activated endo-
thelial cells. Moreover, in vivo, in the CAM (chick cho-
rioallantoic membrane) and cornea assays, adiponectin
decreases angiogenesis and induces apoptosis in tumo-
urs, obtained by implanting T241 fibrosarcoma cells in
mice. Other data reported that adiponectin potently
suppresses the migration of human coronary artery
endothelial cells (HCAEC) induced by VEGF, but does
not increase endothelial cell apoptosis [30]. In a mouse
model of laser-induced choroidal neovascularization,
adiponectin inhibits proliferation of endothelial cells
and inhibits vessel growth [31]. Because of these discre-
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pancies, the aim of our study was to examine the direct
effect of various adiponectin concentrations on the
growth of the murine endothelial cell line HECa10. In
our study, adiponectin was applied separately or in
combination with thalidomide, which is a drug with
immunomodulatory and anti-inflammatory properties
and, in spite of its past, is currently under evaluation
for the treatment of a wide variety of diseases [32]. Tha-
lidomide decreases TNFa production in vitro [33] and
inhibits IL-6 [34] and IL-12 [35] production by monocy-
tes. In contrast, synthesis of IL-2 [36], IL-4, and IL-5 [37]
is enhanced by thalidomide. Thalidomide is thought to
have a strong anti-angiogenic activity in VEGF- and
FGF-2-induced angiogenesis [38, 39], but some results
suggest that this anti-angiogenic effect may only be
observed following species-specific metabolic activation
of the compound [40].
 Material and methods
The murine endothelial cell line HECa10, obtained from
the endothelium of mouse peripheral lymph nodes
immortalized by transfection using a plasmid construct
containing both the gene coding for the large T antigen
of simian virus 40 and the Geneticin resistance gene [41],
was used in the experiments.
The continuous culture of the cells was maintained
in culture flasks (Nunc EasY Flasks 25 cm2, NUNC). The
cells were cultured in RPMI 1640 medium (Sigma) sup-
plemented with 25 mM HEPES buffer (Sigma); 2 g/l so-
dium bicarbonate (Sigma); 50 µM 2-mercaptoethanol
(Sigma); 4 mM L-glutamine (Sigma); 100 U/ml penicil-
lin and 100 µg/ml streptomycin solution (Sigma); 0.1 mM
MEM nonessential amino acid solution (Sigma); 1 mM
sodium pyruvate (Sigma); 10% heat-inactivated fetal calf
serum (FCS, Biochrom) (complete RPMI) at 37∞C in a
humidified atmosphere of 95% air and 5% CO2. Twice
a week, prior to confluency, the cells were harvested
after a 2-minute incubation at room temperature in the
presence of trypsin-EDTA (0.05 and 0.02%, respective-
ly) in a Hanks-balanced salt solution (Sigma). The cells
were collected, washed three times in complete RPMI,
centrifuged, and seeded at 5 ¥ 105 cells in 5 ml of fresh
medium.
After one of the subsequent trypsinization procedu-
res as described above, the cells were suspended in com-
plete RPMI and 50 µl aliquots of cell suspension (2 ¥
103 cells for the 24-hour cell culture and appropriately 4
¥ 103 cells for the 72-hour cell culture) and seeded into
96-well culture plates (Nunclon™ D 96 MicroWell™,
NUNC) containing 130 µl of complete RPMI. After 24
hours of preincubation (37°C, 5% CO2, 95% humidity),
the cells were cultured for a further 24 or 72 hours in
the presence of the examined substances: adiponectin
(previously dissolved in water) at the final concentra-
tions from 10–5M to 10–12M and 10–3M of thalidomide (pre-
viously dissolved in DMSO and then in water) applied
either alone or jointly. In our study we used human adi-
ponectin [Adiponectin (15–36) (Human); Phoenix Phar-
maceuticals, Inc] and thalidomide [(±)–Thalidomide;
Sigma]. An equal volume (20 µl) of serum-free culture
medium was added to the control wells. The cell growth
was assessed by the modified colorimetric Mosmann
method, using the EZ4U kit (EZ4U, 4th Generation Non
Radioactive Cell Proliferation & Cytotoxity Assay, Bio-
medica Gruppe, Austria, Bellco Biomedica) following
the procedure recommended by the manufacturer. This
method is based on the reduction of tetrazolium salt into
a coloured soluble formazan product by mitochondrial
dehydrogenases in the living cells. The intensity of re-
action was estimated via measurement of optical densi-
ty (OD) using an ELISA reader (l = 450 nm).
The obtained data are presented as an OD or as the
percentage of the control group (% of control); they were
statistically analyzed by ANOVA, and the significance
of differences between means was determined by LSD
(Least Significant Differences). Differences were consi-
dered significant if p < 0.05.
Results
We found that adiponectin inhibited the growth of the
murine endothelial cell line HECa 10 at all examined con-
centrations in the 24-hour culture. Its inhibitory effect was
moderate - between 10.5% (10–5M) and 18.8% (10–11M) of
the growth inhibition in comparison to the control gro-
up (Fig. 1, Fig. 2). There were no dose- and time-respon-
se effects (Fig. 2). In the 72-hour cell culture, adiponectin
inhibited the growth only by 10.5% to 14.5% in compari-
son to the control group. Its inhibitory effect was weaker
for the lower concentrations (10–10M and 10–11M) and was
not observed at the concentration of 10–12M (Fig. 2, Fig. 3).
There was no beneficial interaction between adiponec-
tin and thalidomide at the 10–3M concentration. In this
study, however, thalidomide alone did not cause an in-
hibitory effect on this cell line (Fig. 4).
Discussion
Our data show that adiponectin inhibits endothelial cell
growth with a moderate potency, and they are in ac-
cordance with the findings obtained in vitro by Bråken-
hielm et al. [27] and with data from the in vivo study
presented by Tytarenko et al. [31]. Bråkenhielm et al.
[27] observed that the addition of human adiponectin
to BCE cells resulted in a dose-dependent inhibition of
FGF-2-stimulated endothelial proliferation. However,
in our study there were no dose- and time-response ef-
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fects. In in vitro studies which used endothelial cells
derived from large vessels, such as HUVECs, investiga-
tors reported that adiponectin stimulates angiogenesis
[25,26]. Bråkenhielm argued that the reason for these
discrepancies is the size of the vessels used. Similarly to
their study (they used capillary endothelial cells), small
vessels were the source of our endothelial cells, so our
findings seem to confirm this hypothesis. The molecu-
lar form of used adiponectin was different in each stu-
dy. Some investigators [27] applied a recombinant full-
length human adiponectin or mouse adiponectin,
others [25] applied recombinant mouse adiponectin
Figure 1. The effect of various concentrations of adiponectin on the growth of the murine endothelial cell line HECa 10 cultured for 24 h;
hA 10–5, … hA 10–12: adiponectin at concentrations of 10–5M, …10–12M, OD- optical density; Xe ±SEM; * p< 0.05 vs. control group
Rycina 1. Wpływ różnych stężeń adiponektyny na wzrost mysiej linii HECa 10 oceniany po 24 godzinach inkubacji hA 10–5, … hA
10–12: adiponektyna w stężeniu 10–5M, …10–12M, OD — optical density; Xe ± SEM; * p < 0,05 vs. grupa kontrolna
Figure. 2. The effect of various concentrations of adiponectin on the growth of the murine endothelial cell line HECa 10 cultured for 24
h and 72 h; hA 10–5, … hA 10–12: adiponectin at concentrations of 10–5M, …10–12M
Rycina 2. Wpływ różnych stężeń adiponektyny na wzrost mysiej linii HECa 10 oceniany po 24 i 72 godzinach inkubacji hA 10–5, …
hA 10–12: adiponektyna w stężeniu 10–5M, …10–12M
Figure 3. The effect of various concentrations of adiponectin on the growth of the murine endothelial cell line HECa 10 cultured for 72 h;
hA 10–5, … hA 10–12: adiponectin at concentrations of 10–5M, …10–12M, OD — optical density; Xe ± SEM; * p< 0.05 vs. control group
Rycina 3. Wpływ różnych stężeń adiponektyny na wzrost mysiej linii HECa 10 oceniany po 72 godzinach inkubacji hA 10–5, … hA
10–12: adiponektyna w stężeniu 10–5M, …10–12M, OD — optical density; Xe ± SEM; * p< 0,05 vs. grupa kontrolna
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(amid acids 15–247), and we used human adiponectin
(amid acids 15–36). This peptide, according to the re-
commendations, should be rehydrated just before use,
and refreezing any unused portions is not allowed, so
we used adiponectin from one solution for best results
and reproducibility. It is well known that adiponectin
forms different oligomeric complexes [6, 7]. Kobayashi
et al. [26] reported that the HMW fraction of adiponec-
tin suppressed cell death in serum-deprived HUVEC
cultures in a dose-dependent manner, but the trimer or
hexamer form of adiponectin had little effect on endo-
thelial cell survival under these conditions. It is likely
that the different molecular forms of adiponectin used,
and their tendency towards polymerization, also have
some influence on the study results. It is also possible
that there are multiple potential signalling pathways
for adiponectin in endothelial cells and that adiponec-
tin can induce a cascade activation of caspase-8, -9, and
-3, which leads to cell death [27], as well as stimulates
angiogenesis by promoting the cross-talk between the
AMP-activated protein kinase and the Akt signalling
[25]. In our experimental model, we only investigated
whether adiponectin inhibits or stimulates endothelial
cell growth. Moreover, it is also possible that adiponec-
tin inhibits endothelial cell growth (as was shown in
this paper) but promotes endothelial cell migration, sti-
mulates the differentiation of these cells into capillary-
like structures, or has an anti-apoptotic effect toward
endothelial cells [25], and due to all these activities, fi-
nally stimulates angiogenesis. Taking into consideration
Figure 4. The effect of various concentrations of adiponectin and thalidomide, applied either alone or jointly, on the growth of the murine
endothelial cell line HECa 10 cultured for 24 h; hA 10–5, … hA 10–12: adiponectin at concentrations of: 10–5M, …10–12M, T 10–3:
thalidomide at the concentration of 10–3M, DMSO: control for thalidomide
Rycina 4. Wpływ różnych stężeń adiponektyny i talidomidu, zastosowanych osobno lub łącznie na wzrost mysiej linii HECa 10 oceniany
po 24 godzinach inkubacji hA 10–5, … hA 10–12: adiponektyna w stężeniu 10–5M, …10–12M, T 10–3: talidomid w stężeniu 10–3M,
DMSO: kontrola dla talidomidu
the fact that the process of angiogenesis occurs as an
orderly series of events, the apparently contradictory
reports of other researchers may be in accordance with
our results.
Conclusions
The obtained data show that adiponectin inhibits en-
dothelial cell growth and may participate in angioge-
nesis regulation as an endogenous anti-angiogenic fac-
tor, at least at the level of growth processes of endothe-
lial cells.
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